OrthoPediatrics (NASDAQ:KIDS) Earns Buy Rating from BTIG Research

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a report released on Monday, Benzinga reports. They currently have a $29.00 price objective on the stock. BTIG Research’s price objective indicates a potential upside of 29.81% from the company’s previous close.

A number of other brokerages have also commented on KIDS. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Needham & Company LLC lifted their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, Truist Financial set a $22.00 price target on OrthoPediatrics in a research note on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.

OrthoPediatrics Stock Performance

NASDAQ:KIDS opened at $22.34 on Monday. The stock’s 50-day moving average is $22.05 and its 200-day moving average is $19.10. OrthoPediatrics has a 1-year low of $14.42 and a 1-year high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The stock has a market cap of $583.30 million, a P/E ratio of -13.30 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. Equities research analysts anticipate that OrthoPediatrics will post -1.14 earnings per share for the current year.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, Director David R. Pelizzon sold 326,700 shares of OrthoPediatrics stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the completion of the sale, the director directly owned 6,536,764 shares of the company’s stock, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Jennifer N. Pritzker sold 326,700 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the transaction, the insider owned 6,536,764 shares in the company, valued at $150,607,042.56. This represents a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. 32.50% of the stock is currently owned by company insiders.

Institutional Trading of OrthoPediatrics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in OrthoPediatrics during the 2nd quarter valued at $34,000. California State Teachers Retirement System lifted its stake in shares of OrthoPediatrics by 397.1% in the second quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock valued at $87,000 after buying an additional 3,637 shares in the last quarter. Quantinno Capital Management LP acquired a new position in shares of OrthoPediatrics during the first quarter valued at about $160,000. Waverly Advisors LLC bought a new stake in shares of OrthoPediatrics during the first quarter worth about $184,000. Finally, FourThought Financial Partners LLC bought a new stake in shares of OrthoPediatrics during the fourth quarter worth about $197,000. 69.05% of the stock is owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.